New drug IPH4502 targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase study tests a new drug called IPH4502 in people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein called Nectin-4 found on many cancer cells. The main goals are to check the drug's safety, find the best dos…
Phase: PHASE1 • Sponsor: Innate Pharma • Aim: Disease control
Last updated May 08, 2026 12:03 UTC